Klorane Biopharma secures over RMB100 million in A+ financing to advance the development of innovative drugs in cholesterol metabolism.

Cholesgen (Shanghai) Co., Ltd. ("Cholesgen") recently completed its A+ financing round, raising over RMB100 million. The financing round was led by SDIC Venture Capital and was supported by existing investors including AstraZeneca's CIC Healthcare Industry Fund. High-Tech Capital was the lead investor in Cholesgen's A financing round in 2023. The funds raised will be used to accelerate the clinical development of multiple core pipeline candidates and to expand the company's research platform and team.

Cholesgen is focused on the cutting-edge research in the field of lipid and carbohydrate metabolism, targeting innovative drug candidates with high potential for traditional Chinese medicine in the cholesterol metabolism pathway. The company is engaged in the research and development of innovative drugs for major diseases such as metabolic disorders (hyperlipidemia, obesity, diabetes, atherosclerosis, and MASH).

The original research project was derived from the laboratory of Professor Baolai Song, who has been deeply engaged in the field of metabolism for over two decades and is recognized as an international expert in the field of lipid and carbohydrate metabolism. His academic research achievements have been included in classic textbooks of higher disciplines, and numerous articles have been published in top academic journals such as Nature, Science, and Cell. The core R&D team includes several "Jinghui Talents" who are committed to the concept of "healthy metabolism, healthy cardiovascular system, and healthy life" and strive to provide patients with metabolic diseases with treatment options.

Cholesgen expressed its gratitude to SDIC Venture Capital and its existing shareholders for their recognition, trust, and strong support of Cholesgen. The company focuses on original innovative first-in-class targets and establishes R&D cooperation with multinational pharmaceutical companies to continuously advance its pipeline projects. The company also expressed its gratitude to its employees for their hard work and to its partners for their support along the way. In the future, Cholesgen will continue to leverage its competitive advantages, deepen its research in cholesterol metabolism, focus on metabolic and cardiovascular diseases, and accelerate the preclinical research and clinical development of its pipeline candidates.